United Therapeutics posts results for terminated Phase 3 ralinepag CPET study
Results were posted for the terminated ROR-PH-302 trial testing ralinepag's effect on exercise capacity in pulmonary arterial hypertension patients.
United Therapeutics had one notable update this cycle involving its ralinepag pulmonary arterial hypertension program.
- Results were posted on 2026-07-06 for "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy" (NCT04084678, ROR-PH-302, acronym CAPACITY). The trial was designed to assess safety and effects on exercise capacity, measured by cardiopulmonary exercise testing, in WHO Group 1 pulmonary hypertension patients who had recently started therapy.1 The study's overall status is terminated, with the sponsor citing its own decision as the reason for stopping.1 Enrollment reached 10 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.